Enabling Research

WC2B 4AN (London)

Start Date End Date Funded Value Relevance

CSV

25 50 100

£1,744,166

Jul 16 - Mar 19

Development of rAAV-mediated gene therapy for a severe paediatric metabolic liver disease: Ornithine Transcarbamylase deficiency.

MRC award to University College London and Paul Gissen

£3,973,977

Jul 19 - Nov 22

Phase I/II clinical trial evaluating AAV-mediated gene therapy for a severe paediatric metabolic liver disease: Ornithine Transcarbamylase deficiency

MRC award to University College London and Paul Gissen

{{facetGroup.name}}

{{getFilterText(facet,showCount)}}